Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey
- PMID: 30878532
- PMCID: PMC6426700
- DOI: 10.1016/j.pvr.2019.03.002
Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey
Abstract
Cervical cancer is the fourth most common cancer among women in the world. It is estimated that one woman dies every 2 min from cervical cancer. Nearly all cervical cancers are preventable by early detection and treatment through screening or HPV vaccination. In 2018, World Health Organization (WHO) made a global call for action toward the elimination of cervical cancer. Cervical cancer screening involves a complex organized program, which begins with a call/recall system based on personal invitation of eligible women, followed by participation in screening, and leading to diagnosis, treatment, and management as appropriate. An effective cervical screening program with high coverage is dependent on each country's infrastructure and human resource capacity. Efforts to develop an effective program is particularly challenging in low and middle income countries (LMIC) where resources are limited. For an effective strategy, Turkey redesigned the country's cervical screening program. The local call/recall system and centralized monitoring system of individual women were re-vamped with an automated evaluation system. The revised screening program includes the use of primary HPV testing with a well-defined protocol outlining the algorithms of management (i.e., screening intervals and referral), a single nationwide centralized diagnostic laboratory, and a sustainable agreement with the HPV diagnostics industry. This system allows for traceable, real-time monitoring of screening visits and specimens. Turkey reports on the first four years of this re-vamped organized program and shares lessons learnt from the implementation of this new program.
Keywords: Cervical cancer; HPV DNA; Mega HPV lab; Screening; Turkey; WHO.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Figures

Similar articles
-
HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.BMC Womens Health. 2019 Mar 25;19(1):47. doi: 10.1186/s12905-019-0743-0. BMC Womens Health. 2019. PMID: 30909894 Free PMC article.
-
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043. Vaccine. 2013. PMID: 24332297
-
Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.Lancet Public Health. 2017 Feb;2(2):e96-e107. doi: 10.1016/S2468-2667(17)30007-5. Epub 2017 Feb 7. Lancet Public Health. 2017. PMID: 29253402
-
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Vaccine. 2008. PMID: 18847555 Review.
-
[Implementation of National Cervical Cancer Screening Program in France].Bull Cancer. 2019 Mar;106(3):253-261. doi: 10.1016/j.bulcan.2018.11.013. Epub 2019 Jan 8. Bull Cancer. 2019. PMID: 30635113 Review. French.
Cited by
-
HPV prevention in women aged 30-65 in Istanbul: Effect of early diagnosis of cervical cancer.North Clin Istanb. 2022 Aug 24;9(4):304-310. doi: 10.14744/nci.2022.74507. eCollection 2022. North Clin Istanb. 2022. PMID: 36276562 Free PMC article.
-
Evaluation of colposcopy after the addition of human papillomavirus testing to the Turkish cervical cancer screening program.Cancer Med. 2023 Dec;12(24):21751-21760. doi: 10.1002/cam4.6740. Epub 2023 Nov 23. Cancer Med. 2023. PMID: 37994572 Free PMC article.
-
HPV infection - Screening, diagnosis and management of HPV-induced lesions.Rev Bras Ginecol Obstet. 2021 Mar;43(3):240-246. doi: 10.1055/s-0041-1727285. Epub 2021 Apr 15. Rev Bras Ginecol Obstet. 2021. PMID: 33860509 Free PMC article. No abstract available.
-
Overview of organisational methods of primary cervical lesion screening programmes that use human papillomavirus testing.J Med Screen. 2023 Sep;30(3):113-119. doi: 10.1177/09691413231158932. Epub 2023 Mar 28. J Med Screen. 2023. PMID: 36974487 Free PMC article. Review.
-
A new approach for detecting HPV DNA in cervical swabs: comparison of nucleic acid extraction with direct PCR.Virol J. 2025 Jan 11;22(1):8. doi: 10.1186/s12985-024-02601-w. Virol J. 2025. PMID: 39794832 Free PMC article.
References
-
- Ferlay J. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136(5):E359–E386. - PubMed
-
- WHO . 2018. Call to Action for Elimination of the Cervical Cancer.http://www.who.int/reproductivehealth/DG_Call-to-Action.pdf Available from:
-
- Walboomers J.M. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999;189(1):12–19. - PubMed
-
- Harper D.M., DeMars L.R. HPV vaccines - a review of the first decade. Gynecol. Oncol. 2017;146(1):196–204. - PubMed
-
- WHO . Comprehensive Cervical Cancer Control: A Guide to Essential Practice. World Health Organization Copyright (c) World Health Organization 2014; Geneva: 2014. Guidelines approved by the guidelines review committee. nd. - PubMed